ADC Therapeutics
David Ellis has over 20 years of experience in regulatory affairs, working for various pharmaceutical companies. David started their career at Pfizer in 1997, where they held the role of Assistant Vice President in Global Regulatory Affairs and Wyeth Research until 2010. David then worked as the Senior Director of Regulatory Affairs at Cephalon for a year. From 2011 to 2014, they served as the Vice President of Global Regulatory Affairs at Aptalis Pharma. In 2014, they worked as an Independent Regulatory Consultant before joining ADC Therapeutics in 2015 as the Vice President and Head of Regulatory Affairs.
David Ellis holds a PhD in Molecular Biology from the University of Nottingham.
This person is not in any offices
ADC Therapeutics
2 followers
ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.